Verify an Alzheimer's claim by matching it to records from FDA, NIH, WHO, and CMS. A valid treatment names its FDA approval status, who qualifies, and its brain-bleed warning; a valid prevention claim lists specific modifiable risks. Alzheimer's accounts for an estimated 60-70% of dementia cases, says WHO, among over 57 million people worldwide with nearly 10 million new cases yearly. An amyloid-directed antibody is a prescription drug that targets amyloid protein in the brain.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official notice from FDA — Use this primary source to verify the official announcement.
- Read the official notice from FDA — Use this primary source to verify the official announcement.
Table of Contents
- What counts as an approved Alzheimer's drug?
- Why doctors still say there is no cure
- Who can get the new antibodies under Medicare?
- Which claims are red flags?
What counts as an approved Alzheimer's drug?
FDA converted Leqembi (lecanemab-irmb) for early Alzheimer's to traditional approval after a confirmatory trial verified clinical benefit, according to the FDA approval announcement. It was the first amyloid antibody to make that transition. FDA later gave traditional approval to Kisunla (donanemab-azbt) for adults with Alzheimer's disease, the second drug in this class.
Traditional approval means the maker showed clinical benefit in a confirmatory trial, not only clearance of amyloid. That distinction matters for families weighing hope against risk. Ask which approval a product holds and for which stage of disease.
Why doctors still say there is no cure
NIA states there is no known cure for Alzheimer's, according to NIA treatment guidance. Available prescription drugs only manage symptoms or may slow progression. Patients should discuss options with a doctor.
This frame helps sort headlines. A drug may slow decline for selected early-stage patients without curing disease. A supplement or pill promising a cure does not fit this record.
Who can get the new antibodies under Medicare?
Medicare covers FDA traditionally approved anti-amyloid antibodies only under coverage-with-evidence-development, according to the CMS finalized policy. Coverage requires enrollment in a CMS-approved study or registry.
Patients must also have mild impairment and confirmed amyloid. Check these three points before assuming access: Without all three, a clinic promise of routine Medicare payment is wrong.
- enrollment in a CMS-approved study or registry
- mild cognitive impairment or early-stage status in the label
- confirmed amyloid by test accepted in the coverage terms
Which claims are red flags?
FTC and FDA jointly warned supplement sellers that dietary supplements cannot lawfully claim to prevent, treat, or cure Alzheimer's without competent scientific proof. The 2019 action named firms including Gold Crown, TEK Naturals, and Pure Nootropics. NIA advises treating Alzheimer's cure pills or supplements as a red flag.
Both approved antibodies carry a boxed warning for amyloid-related imaging abnormalities, says the FDA prescribing label. These are brain swelling and micro or macro bleeds, which can be fatal and require baseline and serial MRIs. WHO's July 15 2026 guidelines say up to 45% of dementia risk could be prevented or delayed by addressing factors such as tobacco, inactivity, hypertension, diabetes, isolation, and air pollution, according to the WHO update. Watch for these warning signs: Ask your doctor about amyloid testing and trial or registry status before acting on any claim.
- cure, reversal, or prevention promised for a pill, powder, or supplement
- no FDA approval name, no eligible group, and no brain-bleed warning
- no amyloid test and no registered trial or registry for an antibody offer
